title: Anti-Inflammatory Effect of Dialyzable Leukocyte Extract in Autoimmune Prostatitis: Evaluation in Animal Model.
abstract: Objective.To evaluate the anti-inflammatory properties of Dialyzable Leukocyte Extract (DLE) in a murine model of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).Methods.Histopathological characterization, prostatein Enzyme-Linked Immunosorbent Assay, and immunohistochemical analysis for CD45, TNF-α, IFN-γ, IL-6, IL-17, and IL-4 molecules were done in prostatic Wistar rats treated with DLE, placebo, or Dexamethasone.Results.Histopathological analysis of animals induced to prostatitis showed inflammatory infiltrate, mainly constituted by leucocytes and mast cells as well as Benign Prostatic Hyperplasia. Serum prostatein concentrations were 14 times higher than those displayed by healthy animals. After DLE and Dexamethasone treatments, the inflammatory infiltrate decreased; the tissue morphology was similar to that of a normal prostate, and the prostatein decreased to the basal levels of healthy animals. DLE treatment produced a decreased expression of the cell surface marker CD45 and the proinflammatory cytokines TNF-α, IFN-γ, IL-6, and IL-17. On the other hand, the expression of anti-inflammatory cytokine IL-4 increased in both the Dexamethasone and DLE groups.Conclusion.DLE is able to modulate the inflammatory response in Experimental Autoimmune Prostatitis (EAP).
authors.affiliation: ENMH, Instituto Politécnico Nacional, Ciudad de México, Mexico.
authors.forename: Carlos
authors.initials: C
authors.lastname: Pérez-Alvarado
authors.affiliation: ENMH, Instituto Politécnico Nacional, Ciudad de México, Mexico.
authors.forename: Consuelo
authors.initials: C
authors.lastname: Gómez
authors.affiliation: CBG, Instituto Politécnico Nacional, Cd. Reynosa, TAMPS, Mexico.
authors.forename: Miguel
authors.initials: M
authors.lastname: Reyes
authors.affiliation: Hospital General Milpa Alta, Ciudad de México, Mexico.
authors.forename: Mario
authors.initials: M
authors.lastname: García
authors.affiliation: Hospital de Traumatología, IMSS, Ciudad de México, Mexico.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Pérez
authors.affiliation: Farmainmune, Ciudad de México, Mexico.
authors.forename: Carlos
authors.initials: C
authors.lastname: Pérez de la Mora
authors.affiliation: ENMH, Instituto Politécnico Nacional, Ciudad de México, Mexico.
authors.forename: Virginia
authors.initials: V
authors.lastname: Sanchez
authors.affiliation: ENMH, Instituto Politécnico Nacional, Ciudad de México, Mexico.
authors.forename: D Guillermo
authors.identifier: 0000-0001-9368-3717
authors.initials: DG
authors.lastname: Pérez Ishiwara
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D003907:Dexamethasone; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D020381:Interleukin-17 / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D017493:Leukocyte Common Antigens / Q000096:biosynthesis; D008297:Male; D051379:Mice; D060789:Prostatein / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D011472:Prostatitis / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D014165:Transfer Factor / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D020381:Interleukin-17; D015850:Interleukin-6; D060789:Prostatein; D014165:Transfer Factor; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D003907:Dexamethasone; D017493:Leukocyte Common Antigens; C516771:Ptprc protein, rat